Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
A phase 2/3 trial of KRT-232 in endometrial cancer, run by Kartos Therapeutics, Inc., now recruiting.
Overview
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer is a phase 2/3 interventional study registered as NCT05797831 by Kartos Therapeutics, Inc., with 268 participants planned, started 2023-07-17 and due to reach its primary completion in 2025-08. Interventions recorded: Navtemadlin, Navtemadlin Placebo. Conditions listed: Endometrial Cancer. No results are recorded here; the registry entry is the source.
Setting
A Phase 2/3 Study of Navtemadlin as Maintenance Therapy in Subjects With TP53WT Advanced or Recurrent Endometrial Cancer Who Responded to Chemotherapy
Phase
Phase 2/3
Sponsor
Kartos Therapeutics, Inc.
Registry
Enrolled
268